NuView Life Sciences, Inc

NuView Life Sciences, Inc. (founded: 2005) is at the forefront of revolutionizing cancer diagnosis and treatment with the slogan "Changing the way cancer is diagnosed and treated." As a clinical stage precision oncology company, NuView is pioneering a breakthrough approach by targeting the over-expressed Vasoactive Intestinal Peptide/Pituitary Adenylate Cyclase-activating Peptide Receptor on the surface of various cancer types at the onset of oncogenesis. The company's NV-VPAC1 has shown promising results in clinical trials for the confirmation of cancer both in vitro and in vivo. Notably, this innovative agent is not limited to just identification, but can also be utilized to deliver existing therapeutics and new alpha and beta emitters, accentuating its versatility and potential impact in oncology. NuView's strategic focus on creating a Theranostics solution for patients and clinicians by pairing existing imaging and therapeutic radionuclides with their proprietary agent demonstrates a forward-thinking approach towards addressing unmet clinical needs. The latest milestone in the company's journey is the substantial $90.00M Private Equity Round investment on 03 August 2020, indicating the confidence of investors such as Global Emerging Markets in NuView's innovative vision and potential to transform cancer care. By seamlessly integrating cutting-edge science with clinical application, NuView Life Sciences is poised to make a significant impact in the biotechnology industry.